Our data suggest that HER2-DC1 i.t. combined with anti-HER2 antibodies can be tested as an effective alternative therapeutic strategy to standard chemotherapy combined with anti-HER2 antibodies in HER2pos BC, and indeed supports the general notion that targeted, lower toxicity agents can be combined with DC-based immunotherapy to improve therapeutic outcomes. Here, ERBB2 is linked to breast cancer.